Orion Infusions (DHA:ORIONINFU) COGS-to-Revenue : 0.60 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Orion Infusions COGS-to-Revenue?

Orion Infusions's Cost of Goods Sold for the three months ended in Dec. 2023 was BDT121.6 Mil. Its Revenue for the three months ended in Dec. 2023 was BDT202.7 Mil.

Orion Infusions's COGS to Revenue for the three months ended in Dec. 2023 was 0.60.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Orion Infusions's Gross Margin % for the three months ended in Dec. 2023 was 40.02%.

Orion Infusions COGS-to-Revenue Historical Data

The historical data trend for Orion Infusions's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions COGS-to-Revenue Chart

Orion Infusions Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

0.60

0.59

0.60

Orion Infusions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.61	0.60	0.58	0.61	0.60

Orion Infusions COGS-to-Revenue Calculation

Orion Infusions's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	482.732	/	810.153
	=	0.60

Orion Infusions's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	121.594	/	202.732
	=	0.60

Orion Infusions (DHA:ORIONINFU) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Orion Infusions's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	121.594 / 202.732
	=	40.02 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Orion Infusions COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Orion Infusions's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Orion Infusions (DHA:ORIONINFU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tejgaon Industrial Area, No. 153-154, Dhaka, BGD, 1208

Website

https://www.orioninfusion.com

Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions (DHA:ORIONINFU) Headlines

No Headlines